The nitric oxide- and prostaglandin-independent component of the renal vasodilator effect of thimerosal is mediated by epoxyeicosatrienoic acids

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 3, 2003, Pages 1292-1298

  Chen, Y J ^a   Jiang, H ^a   Quilley, J ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; CYTOCHROME P450; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXYGENASE; EPOXYICOSATRIENOIC ACID; INDOMETACIN; MICONAZOLE; N METHYLSULFONYL 6 (2 PROPARGYLOXYPHENYL)HEXAMIDE; N(G) NITROARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYL GROUP; POTASSIUM CHANNEL; POTASSIUM ION; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; TETRYLAMMONIUM; THIOMERSAL; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ACYLATION; ARACHIDONIC ACID METABOLISM; ARTICLE; ATTENUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME MECHANISM; GAS CHROMATOGRAPHY; HYDROLYSIS; INHIBITION KINETICS; ISOLATION PROCEDURE; KIDNEY PERFUSION; MALE; MASS SPECTROMETRY; NONHUMAN; OXIDATION KINETICS; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RAT; VASCULAR TISSUE; VASODILATATION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; BIOLOGICAL FACTORS; CYTOCHROME P-450 ENZYME SYSTEM; ENDOTHELIUM, VASCULAR; KIDNEY; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGENASES; POTASSIUM CHANNELS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RATS; RATS, WISTAR; THIMEROSAL; VASODILATOR AGENTS;

EID: 0037373093     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.042671     Document Type: Article

References (36)

1. Askari B, Bell-Quilley CP, Fulton D, Quilley J, and McGiff JC (1997) Analysis of eicosanoid mediation of the renal functional effects of hyperchloremia. J Pharmacol Exp Ther 282:101-107.
2. Beny JL (1990) Thimerosal hyperpolarizes arterial smooth muscle in an endothelium-dependent manner. Eur J Pharmacol 185:235-238.
3. + channels; the imidazole ring is not required for inhibitory activity. J Pharmacol Exp Ther 273:266-272.
4. Burke JR, Davern LB, Gregor KR, and Tramposch KM (1997) Leukotriene B4 stimulates the release of arachidonate in human neutrophils via the action of cytosolic phospholipase A. Biochim Biophys Acta 1359:80-88.
5. Cachofeiro V and Nasjletti A (1991) Increased vascular responsiveness to bradykinin in kidneys of spontaneously hypertensive rats. Effect of N-nitro-L-arginine. Hypertension 18:683-688.
6. Campbell WB and Gauthier KM (2002) What is new in endothelium-derived hyperpolarizing factors. Curr Opin Nephrol Hypertens 11:177-183.
7. Campbell WB, Gebremedhin D, Pratt PF, and Harder DR (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415-423.
8. Capdevila JH, Kishore V, Dishman E, Blair IA, and Falck JR (1987) A novel pool of rat liver inositol and ethanolamine phospholipids contains epoxyeicosatrienoic acids (EETs). Biochem Biophys Res Commun 146:638-644.
9. Chaytor AT, Martin PEM, Edwards DH, and Griffith TM (2001) Gap junctional communication underpins EDHF-type relaxations evoked by acetylcholine in the rat hepatic artery. Am J Physiol 280:H2441-H2450.
10. Cohen RA and Vanhoutte PM (1995) Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 92:3337-3349.
11. Crack P and Cocks T (1992) Thimerosal blocks stimulated but not basal release of endothelium-derived relaxing factor (EDRF) in dog isolated coronary artery. Br J Pharmacol 107:566-572.
12. Doughty JM, Plane F, and Langton PD (1999) Charybdotoxin and apamin block EDHF in rat mesenteric artery if selectively applied to the endothelium. Am J Physiol 276:H1107-H1112.
13. + is an endothelium-dependent hyperpolarizing factor in rat arteries. Nature (Lond) 396: 269-272.
14. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R (1999) Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature (Lond) 401:493-497.
15. Forstermann U, Burgwitz K, and Frolich JC (1986a) Thimerosal induces endothelium-dependent vascular smooth muscle relaxations by interacting with thiol groups. Relaxations are likely to be mediated by endothelium-derived relaxing factor. Naunyn-Schmiedeberg's Arch Pharmacol 334:501-507.
16. Forstermann U, Goppelt-Strube M, Frolich JC, and Busse R (1986b) Inhibitors of acyl-coenzyme A:lysolecithin acyltransferase activate the production of endothelium-derived vascular relaxing factor. J Pharmacol Exp Ther 238:352-359.
17. Fulton D, Mahboubi K, McGiff JC, and Quilley J (1995) Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol 114:99-102.
18. Fulton D, McGiff JC, and Quilley J (1992) Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol 107:722-725.
19. + channels in the vasodilator response to bradykinin in the rat heart. Br J Pharmacol 113:954-958.
20. 2 in the nitric oxide-independent vasodilator effect of bradykinin in the rat perfused heart. J Pharmacol Exp Ther 278:518-526.
21. Gericke M, Droogmans G, and Nilius B (1993) Thimerosal induced changes of intracellular calcium in human endothelial cells. Cell Calcium 14:201-207.
22. 2+ entry in human and bovine endothelial cells. J Physiol 482:259-274.
23. Halcox JPJ, Narayanan S, Crames-Joyce L, Mincemoyer R, and Quyyumi AA (2001) Characterization of endothelium-derived hyperpolarizaing factor in human forearm microcirculation. Am J Physiol 280:H2470-H2477.
24. Hecker M, Bara AT, Bauersachs J, and Busse R (1994) Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol 481:407-414.
25. 2. Circ Res 84:53-63.
26. Mombouli JV, Bissiriou I, Agboton VD, and Vanhoutte PM (1996) Bioassay of endothelium-derived hyperpolarizing factor. Biochem Biophys Res Commun 221: 484-488.
27. 2+ release in intact HeLa cells seen with aequorin targeted to the endoplasmic reticulum. Cell Calcium 30:181-190.
28. Oyekan AO, Youssef T, Fulton D, Quilley J, and McGiff JC (1999) Renal cytochrome P450 ω-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Investig 104:1131-1137.
29. + channels contribute to acetylcholine-induced, NO-dependent vasorelaxation of rat aorta. Med Sci Monit 7:1129-1136.
30. + channels. Br J Pharmacol 118:1504-1508.
31. Roman RJ (2002) P450 metabohtes of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
32. Rosenblum WI, Nishimura H, Ellis EF, and Nelson GH (1992) The endotheliumdependent effects of thimerosal on mouse pial arterioles in vivo: evidence for control of microvascular events by EDRF as well as prostaglandins. J Cereb Blood Flow Metab 12:703-706.
33. Rzigalinski BA, Willoughby KA, Hoffman SW, Falck JR, and Ellis EF (1999) Calcium influx factor, further evidence it is 5,6-epoxyeicosatrienoic acid. J Biol Chem 274:175-182.
34. Vane JR, Angaard EE, and Botting RM (1990) Regulatory functions of the vascular endothelium. N Engl J Med 323:27-36.
35. Wang M-H, Brand-Schieber E, Zand B, Nguyen X, Falck JR, Balu N, and Schwartzman ML (1998) Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284:966-973.
36. Zou AP, Imig JD, Kaldunski M, Ortiz de Montellano PR, Sui Z, and Roman RJ (1994) Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol 266:F275-F282.